Defence Therapeutics is a publicly traded precision intracellular drug-delivery company unlocking the full potential of cancer biologics.
Our proprietary Accum® platform enhances intracellular delivery, increasing potency while reducing toxicity in ADCs, radiopharmaceuticals, and other advanced biologic therapies. By solving drug delivery at the cellular level, Accum® enables existing and next-generation assets to become safer, more effective first-line treatments—creating scalable value for partners and better outcomes for patients.
Discover the Technology
Explore Our Pipeline
Download Corporate Deck
The Accum® Advantage
- Intracellular Precision: Accum® overcomes endosomal entrapment, ensuring drugs reach their target.
- Boosted Potency: Preclinical models show up to 60x higher efficacy with Accum®-enhanced therapies.
- Safer Treatments: Stronger results at lower doses reduce side effects and costs.
- Platform Potential: Proven to enhance ADCs, RICs and other biologics
- Strong IP Portfolio: 7 patent families, 6 granted US patents, covering core drug delivery innovations
Pipeline Overview
Our oncology pipeline leverages Accum® across multiple modalities:
ADC Partnerships
- Accum® available for licensing to pharma and biotech to enhance efficacy and overcome dosing challenges.
- Proven in vivo results: up to 60-fold potency increase when added to existing ADCs
Radiopharmaceutical Programs
- Active collaboration with leading national radiopharmaceutical group to develop multiple novel radioimmune conjugate assets
- Exploring co-development partnership with multiple partners to accelerate the development
Why Partner or Invest?
- First-Mover Advantage: pioneering rADCs, the next generation of oncology therapies.
- Massive Market Opportunity: ADCs and radiopharma are two of the fastest-growing oncology segments, with multi-billion-dollar M&A activity (AstraZeneca, Eli Lilly, BMS, Novartis).
- De-risked Licensing Model: partners bear clinical trial costs, while Defence benefits from upfronts, milestones, and royalties.
- Proven Leadership: global team with expertise in oncology, pharma partnerships, regulatory affairs, and finance.
- Undervalued Growth Potential: Defence trades at a fraction of peers that were acquired for billions.
Our Vision
We envision a future where every cancer therapy reaches its full potential. By solving drug delivery at the cellular level, Defence Therapeutics aims to transform existing and next-generation biologics into safe, powerful, first-line, life-changing treatments for patients worldwide.